drugset / Trial / NCT03921294

HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor

NCT03921294

NaSingle-groupOpen-labelTreatment

Summary

This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients (baseline FVIII level \<40%) with and without inhibitors with hemophilic pseudotumors; secondary outcomes will assess changes in quality of life and activity level in treated patients.

Timeline

Start
2019-05-15
Primary completion
2022-03-16
Completion
2022-03-16

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Emicizumab Monoclonal antibody